A preliminary nomogram model for predicting relapse of patients with primary membranous nephropathy
暂无分享,去创建一个
Xuemei Liu | Huifang Wang | Min Li | Dandan Guo | Zixuan Fu | Xiaoying Lai | Chunhui Jiang
[1] Jingye Pan,et al. Prediction model of renal function recovery for primary membranous nephropathy with acute kidney injury , 2022, BMC Nephrology.
[2] Zhuoli Zhang,et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. , 2022, Rheumatology.
[3] Li Zhu,et al. Influencing Factors of Recurrence of Nonvalvular Atrial Fibrillation after Radiofrequency Catheter Ablation and Construction of Clinical Nomogram Prediction Model , 2022, International journal of clinical practice.
[4] Gabriel Ștefan,et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy , 2022, Renal failure.
[5] B. Rovin,et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases , 2021, KIDNEYS.
[6] Lijie He,et al. Microhematuria Enhances the Risks of Relapse and Renal Progression in Primary Membranous Nephropathy , 2021, Frontiers in Medicine.
[7] Liang Zhao,et al. Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy , 2021, International Urology and Nephrology.
[8] V. Tesar,et al. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy , 2021, Frontiers in Immunology.
[9] Hong-mei Wang,et al. The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis , 2020, International Urology and Nephrology.
[10] Xin J. Zhou,et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases , 2020, Scientific Reports.
[11] Yusuke Suzuki,et al. Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS) , 2020, Clinical and Experimental Nephrology.
[12] Yusuke Suzuki,et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS) , 2020, Clinical and Experimental Nephrology.
[13] H. Reich,et al. Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy , 2020, Kidney international reports.
[14] Fan Lin,et al. Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy , 2019, International Urology and Nephrology.
[15] B. Rovin,et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. , 2019, The New England journal of medicine.
[16] C. Herencia,et al. Glomerular Hematuria: Cause or Consequence of Renal Inflammation? , 2019, International journal of molecular sciences.
[17] M. Ando,et al. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan , 2018, Renal failure.
[18] J. Wetzels,et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. , 2018, Kidney international.
[19] G. Remuzzi,et al. Treatment of membranous nephropathy: time for a paradigm shift , 2017, Nature Reviews Nephrology.
[20] Sohee Oh,et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy , 2017, BMC Nephrology.
[21] D. Cattran,et al. Membranous nephropathy: integrating basic science into improved clinical management. , 2017, Kidney international.
[22] V. Jha,et al. Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide , 2017, Kidney international reports.
[23] Jun Zhou,et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. , 2017, Autoimmunity reviews.
[24] K. Nath,et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.
[25] V. Jha,et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial , 2016, Nephrology.
[26] Yuanyuan Xie,et al. Association of Relapse with Renal Outcomes under the Current Therapy Regimen for IgA Nephropathy: A Multi-Center Study , 2015, PloS one.
[27] A. Thompson,et al. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[28] G. Remuzzi,et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[29] Sana F. Khan,et al. Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[30] Chapter 7: Idiopathic membranous nephropathy , 2012, Kidney international supplements.
[31] David M. Beck,et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.
[32] B. Rovin,et al. Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.
[33] Kwanghee Kim,et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.
[34] A. Wasilewska,et al. High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome , 2007, Pediatric Nephrology.
[35] S. Haffner,et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. , 2000, Kidney international.
[36] K. Dahan,et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. , 2017, Journal of the American Society of Nephrology : JASN.
[37] J. Wetzels,et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. , 2014, Journal of the American Society of Nephrology : JASN.